To include your compound in the COVID-19 Resource Center, submit it here.

Stealth begins Phase II/III of elamipretide in Barth syndrome

Stealth BioTherapeutics Inc. (Newton, Mass.) began the double-blind, crossover, U.S. Phase II/III TAZPOWER trial to evaluate subcutaneous elamipretide (MTP-131)

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE